Literature DB >> 19399678

High dose rate radiation treatment of experimental intramuscular prostate carcinoma.

Christina Skourou1, P Jack Hoopes, Summer L Gibbs-Strauss, David J Gladstone, Rendall Strawbridge, Keith D Paulsen.   

Abstract

PURPOSE: The Dunning R3327-MLL is a well established transplanted tumour line, and as such it makes a desirable model for evaluative studies of therapy. In the current study, the interstitial growth characteristics as well as the response of this tumour to a single fraction of high dose rate radiation is investigated.
MATERIALS AND METHODS: The in vitro response to radiation of the Dunning R3327-MLL was studied via a colony forming assay using a Cs-137 irradiator. In vitro radiosensitivity was determined on tumours implanted intramuscularly in the left gastrocnemius muscle of the rat and irradiated using an Ir-192 afterloader.
RESULTS: The results demonstrate a faster growth rate when compared to the reported subcutaneous growth rates. The Dunning R3327-MLL's radiosensitivity is comparable to that of late response tissues. The dose required to achieve a specific radiobiological response (the alpha:beta ratio) of the in vitro cell line is 2.4 Gy, whereas the ratio for the intramuscularly growing tumour was 0.99 Gy.
CONCLUSIONS: These findings signify the intramuscularly implanted Dunning R3327-MLL tumour model as a desirable model for the study of single fraction high dose rate radiation treatments.

Entities:  

Mesh:

Year:  2009        PMID: 19399678      PMCID: PMC2798569          DOI: 10.1080/09553000902781139

Source DB:  PubMed          Journal:  Int J Radiat Biol        ISSN: 0955-3002            Impact factor:   2.694


  29 in total

Review 1.  The Dunning model.

Authors:  T R Tennant; H Kim; M Sokoloff; C W Rinker-Schaeffer
Journal:  Prostate       Date:  2000-06-01       Impact factor: 4.104

2.  Dose-dependent differential effects of low and pulsed dose-rate brachytherapy in a radioresistant syngenic rat prostate tumour model.

Authors:  W Harms; P Peschke; K J Weber; F W Hensley; G Wolber; J Debus; M Wannenmacher
Journal:  Int J Radiat Biol       Date:  2002-07       Impact factor: 2.694

3.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations.

Authors:  Mark J Rivard; Bert M Coursey; Larry A DeWerd; William F Hanson; M Saiful Huq; Geoffrey S Ibbott; Michael G Mitch; Ravinder Nath; Jeffrey F Williamson
Journal:  Med Phys       Date:  2004-03       Impact factor: 4.071

4.  Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer.

Authors:  J K Smolev; W D Heston; W W Scott; D S Coffey
Journal:  Cancer Treat Rep       Date:  1977 Mar-Apr

Review 5.  Peritumoral edema.

Authors:  H M Bartkowski
Journal:  Prog Exp Tumor Res       Date:  1984

6.  Intratumoral delivery of paclitaxel for treatment of orthotopic prostate cancer.

Authors:  Sergey Shikanov; Ariella Shikanov; Ofer Gofrit; Abraham Nyska; Benjamin Corn; Abraham J Domb
Journal:  J Pharm Sci       Date:  2009-03       Impact factor: 3.534

7.  The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.

Authors:  J T Isaacs; G W Yu; D S Coffey
Journal:  Invest Urol       Date:  1981-07

8.  Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-HI, and R-3327-AT.

Authors:  J T Isaacs; W D Heston; R M Weissman; D S Coffey
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

9.  Feasibility studies of electrical impedance spectroscopy for early tumor detection in rats.

Authors:  Christina Skourou; P Jack Hoopes; Rendall R Strawbridge; Keith D Paulsen
Journal:  Physiol Meas       Date:  2004-02       Impact factor: 2.833

10.  The radiation sensitivities of R3327-H and R3327-AT rat prostate adenocarcinomas.

Authors:  C Thorndyke; B E Meeker; G Thomas; W H Lakey; M S McPhee; J D Chapman
Journal:  J Urol       Date:  1985-07       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.